Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Mini-Review Article

The Mechanisms of Action of Botulinum Toxin Type A in Nociceptive and Neuropathic Pathways in Cancer Pain

Author(s): Samuel Reyes-Long, Alfonso Alfaro-Rodríguez, Jose Luis Cortes-Altamirano, Eleazar Lara-Padilla, Elizabeth Herrera-Maria, Pablo Romero-Morelos, Mauricio Salcedo and Cindy Bandala*

Volume 28, Issue 15, 2021

Published on: 06 August, 2020

Page: [2996 - 3009] Pages: 14

DOI: 10.2174/0929867327666200806105024

Price: $65

Abstract

Background: Botulinum toxin type A (BoNT-A) is widely employed for cosmetic purposes and in the treatment of certain diseases such as strabismus, hemifacial spasm and focal dystonia among others. BoNT-A effect mainly acts at the muscular level by inhibiting the release of acetylcholine at presynaptic levels consequently blocking the action potential in the neuromuscular junction. Despite the great progress in approval and pharmaceutical usage, improvement in displacing BoNT-A to other pathologies has remained very limited. Patients under diagnosis of several types of cancer experience pain in a myriad of ways; it can be experienced as hyperalgesia or allodynia, and the severity of the pain depends, to some degree, on the place where the tumor is located. Pain relief in patients diagnosed with cancer is not always optimal, and as the disease progresses, transition to more aggressive drugs, like opioids is sometimes unavoidable. In recent years BoNT-A employment in cancer has been explored, as well as an antinociceptive drug; experiments in neuropathic, inflammatory and acute pain have been carried out in animal models and humans. Although its mechanism has not been fully known, evidence has shown that BoNT-A inhibits the secretion of pain mediators (substance P, Glutamate, and calcitonin gene related protein) from the nerve endings and dorsal root ganglion, impacting directly on the nociceptive transmission through the anterolateral and trigeminothalamic systems.

Aim: The study aimed to collect available literature regarding molecular, physiological and neurobiological evidence of BoNT-A in cancer patients suffering from acute, neuropathic and inflammatory pain in order to identify possible mechanisms of action in which the BoNT-A could impact positively in pain treatment.

Conclusion: BoNT-A could be an important neo-adjuvant and coadjuvant in the treatment of several types of cancer, to diminish pro-tumor activity and secondary pain.

Keywords: Botulinum toxin type A, nociception, cancer, neuropathic pain, nociceptive pain, glutamate.

« Previous Next »
[1]
Arezzo, J.C. Possible mechanisms for the effects of botulinum toxin on pain. Clin. J. Pain, 2002, 18(6 Suppl.), S125-S132.
[http://dx.doi.org/10.1097/00002508-200211001-00003] [PMID: 12569959]
[2]
Intiso, D.; Basciani, M.; Santamato, A.; Intiso, M.; Di Rienzo, F. Botulinum toxin type A for the treatment of neuropathic pain in neuro-rehabilitation. Toxins (Basel), 2015, 7(7), 2454-2480.
[http://dx.doi.org/10.3390/toxins7072454] [PMID: 26134256]
[3]
Oh, H.M.; Chung, M.E. Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel), 2015, 7(8), 3127-3154.
[http://dx.doi.org/10.3390/toxins7083127] [PMID: 26287242]
[4]
Patil, S.; Willett, O.; Thompkins, T.; Hermann, R.; Ramanathan, S.; Cornett, E.M.; Fox, C.J.; Kaye, A.D. Botulinum toxin: pharmacology and therapeutic roles in pain states. Curr. Pain Headache Rep., 2016, 20(3), 15.
[http://dx.doi.org/10.1007/s11916-016-0545-0] [PMID: 26879873]
[5]
Wheeler, A.; Smith, H.S. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology, 2013, 306, 124-146.
[http://dx.doi.org/10.1016/j.tox.2013.02.006] [PMID: 23435179]
[6]
Aoki, K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology, 2005, 26(5), 785-793.
[http://dx.doi.org/10.1016/j.neuro.2005.01.017] [PMID: 16002144]
[7]
Lang, A.M. Botulinum toxin type A therapy in chronic pain disorders. Arch. Phys. Med. Rehabil., 2003, 84(3 Suppl. 1), S69-S73.
[http://dx.doi.org/10.1053/apmr.2003.50121] [PMID: 12708561]
[8]
Cobianchi, S.; Jaramillo, J.; Luvisetto, S.; Pavone, F.; Navarro, X. Botulinum neurotoxin A promotes functional recovery after peripheral nerve injury by increasing regeneration of myelinated fibers. Neuroscience, 2017, 359, 82-91.
[http://dx.doi.org/10.1016/j.neuroscience.2017.07.011] [PMID: 28716587]
[9]
Cui, M.; Khanijou, S.; Rubino, J.; Aoki, K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain, 2004, 107(1-2), 125-133.
[http://dx.doi.org/10.1016/j.pain.2003.10.008] [PMID: 14715398]
[10]
Matak, I.; Tékus, V.; Bölcskei, K.; Lacković, Z.; Helyes, Z. Involvement of substance P in the antinociceptive effect of botulinum toxin type A: evidence from knockout mice. Neuroscience, 2017, 358, 137-145.
[http://dx.doi.org/10.1016/j.neuroscience.2017.06.040] [PMID: 28673722]
[11]
Aoki, K.R.; Francis, J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat. Disord., 2011, 17(Suppl. 1), S28-S33.
[http://dx.doi.org/10.1016/j.parkreldis.2011.06.013] [PMID: 21999893]
[12]
Brin, M.F.; Fahn, S.; Moskowitz, C.; Friedman, A.; Shale, H.M.; Greene, P.E.; Blitzer, A.; List, T.; Lange, D.; Lovelace, R.E.; McMahon, D. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord., 1987, 2(4), 237-254.
[http://dx.doi.org/10.1002/mds.870020402] [PMID: 3504553]
[13]
Tsui, J.K.C.; Eisen, A.; Stoessl, A.J.; Calne, S.; Calne, D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, 1986, 2(8501), 245-247.
[http://dx.doi.org/10.1016/S0140-6736(86)92070-2] [PMID: 2874278]
[14]
Vacca, V.; Marinelli, S.; Luvisetto, S.; Pavone, F. Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opioid receptor expression in neuropathic mice. Brain Behav. Immun., 2013, 32, 40-50.
[http://dx.doi.org/10.1016/j.bbi.2013.01.088] [PMID: 23402794]
[15]
Yen, C-T.; Lu, P-L. Thalamus and Pain. Acta Anaesthesiol. Taiwan., 2013, 51(2), 73-80.
[http://dx.doi.org/10.1016/j.aat.2013.06.011] [PMID: 23968658]
[16]
Rahn, E.J.; Guzman-Karlsson, M.C.; David Sweatt, J. Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory. Neurobiol. Learn. Mem., 2013, 105, 133-150.
[http://dx.doi.org/10.1016/j.nlm.2013.06.008] [PMID: 23796633]
[17]
Legrain, V.; Iannetti, G.D.; Plaghki, L.; Mouraux, A. The pain matrix reloaded: a salience detection system for the body. Prog. Neurobiol., 2011, 93(1), 111-124.
[http://dx.doi.org/10.1016/j.pneurobio.2010.10.005] [PMID: 21040755]
[18]
Schmidt, B.L.; Hamamoto, D.T.; Simone, D.A.; Wilcox, G.L. Mechanism of cancer pain. Mol. Interv., 2010, 10(3), 164-178.
[http://dx.doi.org/10.1124/mi.10.3.7] [PMID: 20539035]
[19]
Rosso, M.; Muñoz, M.; Berger, M. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal, 2012, 2012, 381434.
[http://dx.doi.org/10.1100/2012/381434] [PMID: 22545017]
[20]
Stepulak, A.; Rola, R.; Polberg, K.; Ikonomidou, C. Glutamate and its receptors in cancer. J. Neural Transm. (Vienna), 2014, 121(8), 933-944.
[http://dx.doi.org/10.1007/s00702-014-1182-6] [PMID: 24610491]
[21]
Hodgson, A.; Pakbaz, S.; Tayyari, F.; Young, J.E.M.; Mete, O. Diagnostic pitfall: parathyroid carcinoma expands the spectrum of calcitonin and calcitonin gene-related peptide expressing neuroendocrine neoplasms. Endocr. Pathol., 2019, 30(2), 168-172.
[http://dx.doi.org/10.1007/s12022-019-9572-9] [PMID: 30903444]
[22]
Schmidt, B.L. The neurobiology of cancer pain. Neuroscientist, 2014, 20(5), 546-562.
[http://dx.doi.org/10.1177/1073858414525828] [PMID: 24664352]
[23]
Majima, M.; Ito, Y.; Hosono, K.; Amano, H. CGRP/CGRP receptor antibodies: potential adverse effects due to blockade of neovascularization? Trends Pharmacol. Sci., 2019, 40(1), 11-21.
[http://dx.doi.org/10.1016/j.tips.2018.11.003] [PMID: 30502971]
[24]
Weber, L.V.; Al-Refae, K.; Wölk, G.; Bonatz, G.; Altmüller, J.; Becker, C.; Gisselmann, G.; Hatt, H. Expression and functionality of TRPV1 in breast cancer cells. Breast Cancer (Dove Med. Press), 2016, 8(8), 243-252.
[http://dx.doi.org/10.2147/BCTT.S121610] [PMID: 28008282]
[25]
Wakabayashi, H.; Wakisaka, S.; Hiraga, T.; Hata, K.; Nishimura, R.; Tominaga, M.; Yoneda, T. Decreased sensory nerve excitation and bone pain associated with mouse Lewis lung cancer in TRPV1-deficient mice. J. Bone Miner. Metab., 2018, 36(3), 274-285.
[http://dx.doi.org/10.1007/s00774-017-0842-7] [PMID: 28516219]
[26]
Zhang, S.; Zhao, J.; Meng, Q. AAV-mediated siRNA against TRPV1 reduces nociception in a rat model of bone cancer pain. Neurol. Res., 2019, 41(11), 972-979.
[http://dx.doi.org/10.1080/01616412.2019.1639317] [PMID: 31296147]
[27]
Maqboul, A.; Elsadek, B. A novel model of cancer-induced peripheral neuropathy and the role of TRPA1 in pain transduction. Pain Res. Manag., 2017, 2017, 3517207.
[http://dx.doi.org/10.1155/2017/3517207] [PMID: 30510606]
[28]
Di Virgilio, F.; Jiang, L-H.; Roger, S.; Falzoni, S.; Sarti, A.C.; Vultaggio-Poma, V.; Chiozzi, P.; Adinolfi, E. Structure, function and techniques of investigation of the P2X7 receptor (P2X7R) in mammalian cells. Methods Enzymol., 2019, 629, 115-150.
[http://dx.doi.org/10.1016/bs.mie.2019.07.043] [PMID: 31727237]
[29]
Zhi, X.; Li, B.; Li, Z.; Zhang, J.; Yu, J.; Zhang, L.; Xu, Z. Adrenergic modulation of AMPK dependent autophagy by chronic stress enhances cell proliferation and survival in gastric cancer. Int. J. Oncol., 2019, 54(5), 1625-1638.
[http://dx.doi.org/10.3892/ijo.2019.4753] [PMID: 30896863]
[30]
Jakobsen, A-M.; Ahlman, H.; Wängberg, B.; Kölby, L.; Bengtsson, M.; Nilsson, O. Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas. J. Pathol., 2002, 196(1), 44-50.
[http://dx.doi.org/10.1002/path.1002] [PMID: 11748641]
[31]
Bandala, C.; Cortés-Algara, A.L.; Mejía-Barradas, C.M.; Ilizaliturri-Flores, I.; Dominguez-Rubio, R.; Bazán-Méndez, C.I.; Floriano-Sánchez, E.; Luna-Arias, J.P.; Anaya-Ruiz, M.; Lara-Padilla, E. Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. Int. J. Clin. Exp. Pathol., 2015, 8(7), 8411-8418.
[PMID: 26339411]
[32]
Karsenty, G.; Rocha, J.; Chevalier, S.; Scarlata, E.; Andrieu, C.; Zouanat, F.Z.; Rocchi, P.; Giusiano, S.; Elzayat, E.A.; Corcos, J. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate, 2009, 69(11), 1143-1150.
[http://dx.doi.org/10.1002/pros.20958] [PMID: 19399787]
[33]
Proietti, S.; Nardicchi, V.; Porena, M.; Giannantoni, A. [Botulinum toxin type-A toxin activity on prostate cancer cell lines]. Urologia, 2012, 79(2), 135-141.
[http://dx.doi.org/10.5301/RU.2012.9254] [PMID: 22610840]
[34]
Bandala, C.; Miliar-García, A.; Mejía-Barradas, C.M.; Anaya-Ruiz, M.; Luna-Arias, J.P.; Bazán-Méndez, C.I.; Gómez-López, M.; Juárez-Méndez, S.; Lara-Padilla, E. Synaptic vesicle protein 2 (SV2) isoforms. Asian Pac. J. Cancer Prev., 2012, 13(10), 5063-5067.
[http://dx.doi.org/10.7314/APJCP.2012.13.10.5063] [PMID: 23244111]
[35]
Bandala, C.; Perez-santos, J.L.M.; Lara-padilla, E.; Delgado-Lopez, G.; Anaya-Ruiz, M. Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line. Asian Pac. J. Cancer Prev., 2013, 14(2), 891-894.
[http://dx.doi.org/10.7314/apjcp.2013.14.2.891] [PMID: 23621257]
[36]
Coarfa, C.; Florentin, D.; Putluri, N.; Ding, Y.; Au, J.; He, D.; Ragheb, A.; Frolov, A.; Michailidis, G.; Lee, M.; Kadmon, D.; Miles, B.; Smith, C.; Ittmann, M.; Rowley, D.; Sreekumar, A.; Creighton, C.J.; Ayala, G. Influence of the neural microenvironment on prostate cancer. Prostate, 2018, 78(2), 128-139.
[http://dx.doi.org/10.1002/pros.23454] [PMID: 29131367]
[37]
Hsu, Y.C.; Wang, H.J.; Chuang, Y.C. Intraprostatic botulinum neurotoxin type A injection for benign prostatic hyperplasia-a spotlight in reality. Toxins (Basel), 2016, 8(5), 2-9.
[http://dx.doi.org/10.3390/toxins8050126] [PMID: 27128942]
[38]
Welch, M.J.; Purkiss, J.R.; Foster, K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon, 2000, 38(2), 245-258.
[http://dx.doi.org/10.1016/S0041-0101(99)00153-1] [PMID: 10665805]
[39]
McMahon, H.T.; Foran, P.; Dolly, J.O.; Verhage, M.; Wiegant, V.M.; Nicholls, D.G. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J. Biol. Chem., 1992, 267(30), 21338-21343.
[PMID: 1356988]
[40]
Paterson, K.; Lolignier, S.; Wood, J.N.; McMahon, S.B.; Bennett, D.L.H. Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann. Neurol., 2014, 75(4), 591-596.
[http://dx.doi.org/10.1002/ana.24122] [PMID: 24550077]
[41]
Park, J.; Chung, M.E. Botulinum toxin for central neuropathic pain. Toxins (Basel), 2018, 10(6), 224.
[http://dx.doi.org/10.3390/toxins10060224] [PMID: 29857568]
[42]
Park, J.; Park, H.J. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel), 2017, 9(9), 260.
[http://dx.doi.org/10.3390/toxins9090260] [PMID: 28837075]
[43]
Melzack, R. Katz. J. Pain. Wiley Interdiscip. Rev. Cogn. Sci., 2013, 4(1), 1-15.
[http://dx.doi.org/10.1002/wcs.1201] [PMID: 26304172]
[44]
Nickel, F.T.; Seifert, F.; Lanz, S.; Maihöfner, C. Mechanisms of neuropathic pain. Eur. Neuropsychopharmacol., 2012, 22(2), 81-91.
[http://dx.doi.org/10.1016/j.euroneuro.2011.05.005] [PMID: 21672666]
[45]
Luvisetto, S.; Marinelli, S.; Cobianchi, S.; Pavone, F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience, 2007, 145(1), 1-4.
[http://dx.doi.org/10.1016/j.neuroscience.2006.12.004] [PMID: 17218063]
[46]
Antonucci, F.; Rossi, C.; Gianfranceschi, L.; Rossetto, O.; Caleo, M. Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci., 2008, 28(14), 3689-3696.
[http://dx.doi.org/10.1523/JNEUROSCI.0375-08.2008] [PMID: 18385327]
[47]
Favre-Guilmard, C.; Auguet, M.; Chabrier, P.E. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur. J. Pharmacol., 2009, 617(1-3), 48-53.
[http://dx.doi.org/10.1016/j.ejphar.2009.06.047] [PMID: 19576881]
[48]
Xiao, L.; Cheng, J.; Dai, J.; Zhang, D. Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats. Pain Med., 2011, 12(9), 1385-1394.
[http://dx.doi.org/10.1111/j.1526-4637.2011.01182.x] [PMID: 21810163]
[49]
Borodic, G.E.; Acquadro, M.A. The use of botulinum toxin for the treatment of chronic facial pain. J. Pain, 2002, 3(1), 21-27.
[http://dx.doi.org/10.1054/jpai.2002.27142] [PMID: 14622850]
[50]
Allam, N.; Brasil-Neto, J.P.; Brown, G.; Tomaz, C. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin. J. Pain, 2005, 21(2), 182-184.
[http://dx.doi.org/10.1097/00002508-200503000-00010] [PMID: 15722812]
[51]
Piovesan, E.J.; Teive, H.G.; Kowaks, P.A.; Della Coletta, M.V.; Werneck, L.C.; Silberstein, S.D. An open study of botulinum-a toxin treatment of trigeminal neuralgia. Neurology, 2005, 65(8), 1306-1308.
[http://dx.doi.org/10.1212/01.wnl.0000180940.98815.74] [PMID: 16247065]
[52]
Türk, U.; Ilhan, S.; Alp, R.; Sur, H. Botulinum toxin and intractable trigeminal neuralgia. Clin. Neuropharmacol., 2005, 28(4), 161-162.
[http://dx.doi.org/10.1097/01.wnf.0000172497.24770.b0] [PMID: 16062093]
[53]
Zúñiga, C.; Díaz, S.; Piedimonte, F.; Micheli, F. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq. Neuropsiquiatr., 2008, 66(3A), 500-503.
[http://dx.doi.org/10.1590/s0004-282x2008000400012] [PMID: 18813708]
[54]
Ngeow, W.C.; Nair, R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2010, 109(3), e47-e50.
[http://dx.doi.org/10.1016/j.tripleo.2009.03.021] [PMID: 20219585]
[55]
Yoon, S.H.; Merrill, R.L.; Choi, J.H.; Kim, S.T. Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Med., 2010, 11(4), 630-632.
[http://dx.doi.org/10.1111/j.1526-4637.2010.00801.x] [PMID: 20210871]
[56]
Bohluli, B.; Motamedi, M.H.K.; Bagheri, S.C.; Bayat, M.; Lassemi, E.; Navi, F.; Moharamnejad, N. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2011, 111(1), 47-50.
[http://dx.doi.org/10.1016/j.tripleo.2010.04.043] [PMID: 20674409]
[57]
Wu, C.J.; Lian, Y.J.; Zheng, Y.K.; Zhang, H.F.; Chen, Y.; Xie, N.C.; Wang, L.J. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia, 2012, 32(6), 443-450.
[http://dx.doi.org/10.1177/0333102412441721] [PMID: 22492424]
[58]
Layeeque, R.; Hochberg, J.; Siegel, E.; Kunkel, K.; Kepple, J.; Henry-Tillman, R.S.; Dunlap, M.; Seibert, J.; Klimberg, V.S. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann. Surg., 2004, 240(4), 608-613.
[http://dx.doi.org/10.1097/01.sla.0000141156.56314.1f] [PMID: 15383788]
[59]
Kapural, L.; Stillman, M.; Kapural, M.; McIntyre, P.; Guirgius, M.; Mekhail, N. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract., 2007, 7(4), 337-340.
[http://dx.doi.org/10.1111/j.1533-2500.2007.00150.x] [PMID: 17986166]
[60]
Ranoux, D.; Attal, N.; Morain, F.; Bouhassira, D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol., 2008, 64(3), 274-283.
[http://dx.doi.org/10.1002/ana.21427] [PMID: 18546285]
[61]
Yuan, R.Y.; Sheu, J.J.; Yu, J.M.; Chen, W.T.; Tseng, I.J.; Chang, H.H.; Hu, C.J. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology, 2009, 72(17), 1473-1478.
[http://dx.doi.org/10.1212/01.wnl.0000345968.05959.cf] [PMID: 19246421]
[62]
Sotiriou, E.; Apalla, Z.; Panagiotidou, D.; Ioannidis, D. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm. Venereol., 2009, 89(2), 214-215.
[http://dx.doi.org/10.2340/00015555-0609] [PMID: 19326024]
[63]
Xiao, L.; Mackey, S.; Hui, H.; Xong, D.; Zhang, Q.; Zhang, D. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med., 2010, 11(12), 1827-1833.
[http://dx.doi.org/10.1111/j.1526-4637.2010.01003.x] [PMID: 21134121]
[64]
Apalla, Z.; Sotiriou, E.; Lallas, A.; Lazaridou, E.; Ioannides, D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin. J. Pain, 2013, 29(10), 857-864.
[http://dx.doi.org/10.1097/AJP.0b013e31827a72d2] [PMID: 23370074]
[65]
Burns, P.B.; Rohrich, R.J.; Chung, K.C. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg., 2011, 128(1), 305-310.
[http://dx.doi.org/10.1097/PRS.0b013e318219c171] [PMID: 21701348]
[66]
Moon, Y.E.; Choi, J.H.; Park, H.J.; Park, J.H.; Kim, J.H. Ultrasound-guided nerve block with botulinum toxin type A for intractable neuropathic pain. Toxins (Basel), 2016, 8(1), 18.
[http://dx.doi.org/10.3390/toxins8010018] [PMID: 26761032]
[67]
Han, Z.A.; Song, D.H.; Oh, H.M.; Chung, M.E. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann. Neurol., 2016, 79(4), 569-578.
[http://dx.doi.org/10.1002/ana.24605] [PMID: 26814620]
[68]
Attal, N.; de Andrade, D.C.; Adam, F.; Ranoux, D.; Teixeira, M.J.; Galhardoni, R.; Raicher, I.; Üçeyler, N.; Sommer, C.; Bouhassira, D. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2016, 15(6), 555-565.
[http://dx.doi.org/10.1016/S1474-4422(16)00017-X] [PMID: 26947719]
[69]
Ding, X.D.; Zhong, J.; Liu, Y.P.; Chen, H.X. Botulinum as a toxin for treating post-herpetic neuralgia. Iran. J. Public Health, 2017, 46(5), 608-611.
[PMID: 28560190]
[70]
Liu, J.; Xu, Y.Y.; Zhang, Q.L.; Luo, W.F. Efficacy and safety of botulinum toxin type A in treating patients of advanced age with idiopathic trigeminal neuralgia. Pain Res. Manag., 2018, 2018, 7365148.
[http://dx.doi.org/10.1155/2018/7365148] [PMID: 29849847]
[71]
Mantyh, P.W.; Clohisy, D.R.; Koltzenburg, M.; Hunt, S.P. Molecular mechanisms of cancer pain. Nat. Rev. Cancer, 2002, 2(3), 201-209.
[http://dx.doi.org/10.1038/nrc747] [PMID: 11990856]
[72]
van den Beuken-van Everdingen, M.H.J.; Hochstenbach, L.M.J.; Joosten, E.A.J.; Tjan-Heijnen, V.C.G.; Janssen, D.J.A. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J. Pain Symptom Manage., 2016, 51(6), 1070-1090.e9.
[http://dx.doi.org/10.1016/j.jpainsymman.2015.12.340] [PMID: 27112310]
[73]
Tseng, T.-H.; Lin, C.-C. [Cancer pain]. 2008. Hu Li Za Zhi., 55(2), 16-21.
[PMID: 18393205]
[74]
Middlemiss, T.; Laird, B.J.A.; Fallon, M.T. Mechanisms of cancer-induced bone pain. Clin. Oncol. (R. Coll. Radiol.), 2011, 23(6), 387-392.
[http://dx.doi.org/10.1016/j.clon.2011.03.003] [PMID: 21683564]
[75]
Lozano-Ondoua, A.N.; Symons-Liguori, A.M.; Vanderah, T.W. Cancer-induced bone pain: mechanisms and models. Neurosci. Lett., 2013, 557(Pt A), 52-59.
[http://dx.doi.org/10.1016/j.neulet.2013.08.003] [PMID: 24076008]
[76]
Jung, B.F.; Ahrendt, G.M.; Oaklander, A.L.; Dworkin, R.H. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain, 2003, 104(1-2), 1-13.
[http://dx.doi.org/10.1016/S0304-3959(03)00241-0] [PMID: 12855309]
[77]
Mittal, S.; Machado, D.G.; Jabbari, B. OnabotulinumtoxinA for treatment of focal cancer pain after surgery and/or radiation. Pain Med., 2012, 13(8), 1029-1033.
[http://dx.doi.org/10.1111/j.1526-4637.2012.01437.x] [PMID: 22776097]
[78]
De Groef, A.; Devoogdt, N.; Van Kampen, M.; Nevelsteen, I.; Smeets, A.; Neven, P.; Geraerts, I.; Dams, L.; Van der Gucht, E.; Debeer, P. Effectiveness of botulinum toxin a for persistent upper limb pain after breast cancer treatment: a double-blinded randomized controlled trial. Arch. Phys. Med. Rehabil., 2018, 99(7), 1342-1351.
[http://dx.doi.org/10.1016/j.apmr.2017.12.032] [PMID: 29409922]
[79]
Fabregat, G.; Asensio-Samper, J.M.; Palmisani, S.; Villanueva-Pérez, V.L.; De Andrés, J. Subcutaneous botulinum toxin for chronic post-thoracotomy pain. Pain Pract., 2013, 13(3), 231-234.
[http://dx.doi.org/10.1111/j.1533-2500.2012.00569.x] [PMID: 22716282]
[80]
De Micheli, C.; Fornengo, P.; Bosio, A.; Epifani, G.; Pascale, C. Severe radiation-induced proctitis treated with botulinum anatoxin type A. J. Clin. Oncol., 2003, 21(13), 2627.
[http://dx.doi.org/10.1200/jco.2003.99.030] [PMID: 12829690]
[81]
Naik, H.B.; Steinberg, S.M.; Middelton, L.A.; Hewitt, S.M.; Zuo, R.C.; Linehan, W.M.; Kong, H.H.; Cowen, E.W. Efficacy of intralesional botulinum toxin A for treatment of painful cutaneous leiomyomas: a randomized clinical trial. JAMA Dermatol., 2015, 151(10), 1096-1102.
[http://dx.doi.org/10.1001/jamadermatol.2015.1793] [PMID: 26244563]
[82]
Gabriel, A.; Champaneria, M.C.; Maxwell, G.P. The efficacy of botulinum toxin A in post-mastectomy breast reconstruction: a pilot study. Aesthet. Surg. J., 2015, 35(4), 402-409.
[http://dx.doi.org/10.1093/asj/sjv040] [PMID: 25825421]
[83]
Rostami, R.; Mittal, S.O.; Radmand, R.; Jabbari, B. Incobotulinum toxin-A improves post-surgical and post-radiation pain in cancer patients. Toxins (Basel), 2016, 8(1), 22.
[http://dx.doi.org/10.3390/toxins8010022] [PMID: 26771640]
[84]
Delaney, A.; Fleetwood-Walker, S.M.; Colvin, L.A.; Fallon, M. Translational medicine: cancer pain mechanisms and management. Br. J. Anaesth., 2008, 101(1), 87-94.
[http://dx.doi.org/10.1093/bja/aen100] [PMID: 18492671]
[85]
Schwei, M.J.; Honore, P.; Rogers, S.D.; Salak-Johnson, J.L.; Finke, M.P.; Ramnaraine, M.L.; Clohisy, D.R.; Mantyh, P.W. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J. Neurosci., 1999, 19(24), 10886-10897.
[http://dx.doi.org/10.1523/jneurosci.19-24-10886.1999] [PMID: 10594070]

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy